Search Result

Results for "

RANKL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	RANKL/RANK (17) Akt (4) Antibiotic (1) Apoptosis (4) Autophagy (3) Bacterial (5) Btk (1) Calcineurin (1) CXCR (1) ERK (1) FGFR (1) GLUT (2) Histone Methyltransferase (1) HIV (2) HMG-CoA Reductase (HMGCR) (1) Insulin Receptor (2) Macrophage migration inhibitory factor (MIF) (1) MALT1 (1) MEK (1) NF-κB (15) Nuclear Factor of activated T Cells (NFAT) (3) p38 MAPK (4) Phosphatase (1) PI3K (2) PIN1 (1) Prostaglandin Receptor (3) PROTACs (1) Proton Pump (2) Reactive Oxygen Species (2) STAT (2) STING (1) TNF Receptor (2) Toll-like Receptor (TLR) (4) Wnt (4) β-catenin (4)
By Research Areas:	Cancer (25) Cardiovascular Disease (4) Endocrinology (4) Infection (9) Inflammation/Immunology (21) Metabolic Disease (17) Neurological Disease (3)

By Targets:

RANKL/RANK (17)

Akt (4)

Antibiotic (1)

Apoptosis (4)

Autophagy (3)

Bacterial (5)

Btk (1)

Calcineurin (1)

CXCR (1)

ERK (1)

FGFR (1)

GLUT (2)

Histone Methyltransferase (1)

HIV (2)

HMG-CoA Reductase (HMGCR) (1)

Insulin Receptor (2)

Macrophage migration inhibitory factor (MIF) (1)

MALT1 (1)

MEK (1)

NF-κB (15)

Nuclear Factor of activated T Cells (NFAT) (3)

p38 MAPK (4)

Phosphatase (1)

PI3K (2)

PIN1 (1)

Prostaglandin Receptor (3)

PROTACs (1)

Proton Pump (2)

Reactive Oxygen Species (2)

STAT (2)

STING (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (4)

Wnt (4)

β-catenin (4)

By Research Areas:

Cancer (25)

Cardiovascular Disease (4)

Endocrinology (4)

Infection (9)

Inflammation/Immunology (21)

Metabolic Disease (17)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: RANKL/RANK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9958

Denosumab 1 Publications Verification Immunoglobulin G2; Ranmark	NF-κB	Cancer
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of *RANKL* (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .

HY-147369

NFATc1-IN-1 1 Publications Verification	Nuclear Factor of activated T Cells (NFAT)	Others
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC₅₀ of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .

HY-130304

8-Isoprostaglandin E2 iPE2-III	Prostaglandin Receptor	Cardiovascular Disease
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A₂ (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .

HY-N0277

Aconine 2 Publications Verification Jesaconine	NF-κB	Inflammation/Immunology Cancer
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.

HY-N10838

Ajudecunoid A	Others	Others
Ajudecunoid A is nature product that could be isolated from Ajuga decumbens. Ajudecunoid A inhibits RANKL-Induced osteoclastogenesis .

HY-155960

SH491	Others	Inflammation/Immunology
SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC₅₀: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9) .

HY-149472

Anti-osteoporosis agent-4	NF-κB PI3K	Inflammation/Immunology
Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC₅₀ value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .

HY-W438351

1,3-Dibenzyl-5-fluorouracil	RANKL/RANK	Metabolic Disease
1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .

HY-N12836

Peniditerpenoid A	Others	Metabolic Disease
Peniditerpenoid A is a di-seco-indole diterpenoid. Peniditerpenoid A decreases the expression of p-IkBαby RANKL induced. Peniditerpenoid A inhibits RANKL induced osteoclast differentiation. Peniditerpenoid A has the potential for the research of osteoporosis .

HY-158311

Anti-osteoporosis agent-8	RANKL/RANK p38 MAPK NF-κB	Endocrinology
Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for *RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC₅₀* is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .

HY-P99966

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

HY-110063

4-IPP 3 Publications Verification 4-Iodo-6-phenylpyrimidine	Macrophage migration inhibitory factor (MIF)	Metabolic Disease
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) .

HY-N11514

Anti-osteoporosis agent-2	Others	Inflammation/Immunology
Anti-osteoporosis agent-2 (Compound 10) is an anti-osteoporosis agent. Anti-osteoporosis agent-2 inhibits differentiation on osteoclast induced by RANKL .

HY-N10117

2,3-Bis(3-indolylmethyl)indole	RANKL/RANK	Others
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.

HY-N10062

Amakusamine	RANKL/RANK	Others
Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC₅₀ value of 10.5 μM in RAW264.7 cells.

HY-N12740

Napyradiomycin B4	MEK ERK	Others
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .

HY-N9346

Phlorigidoside C	Others	Inflammation/Immunology
Phlorigidoside C, a natural iridoid glucoside, possesses anti-rheumatoid arthritis effect .

HY-N2119

Sciadopitysin 1 Publications Verification	TNF Receptor NF-κB	Inflammation/Immunology
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .

HY-153675

BCPA	PIN1	Metabolic Disease
BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research .

HY-111266

Halenaquinone	PI3K Apoptosis	Inflammation/Immunology Cancer
Halenaquinone is a phosphatidylinositol 3-kinase inhibitor and can be isolated from the marine sponge Petrosia alfiani. Halenaquinone inhibits RANKL-induced osteoclastogenesis, and induces cell apoptosis in PC12 cells .

HY-N3188

Niloticin	Akt NF-κB	Infection
Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways .

HY-N0499

Cyanidin Chloride 3 Publications Verification IdB 1027	RANKL/RANK	Cancer
Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .

HY-N0656

Usnic acid 1 Publications Verification	Bacterial	Infection Cancer
Usnic acid, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid has excellent anticancer and antimicrobial properties. Usnic acid significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .

HY-N2528

Usnic acid sodium	Bacterial	Infection Cancer
Usnic acid sodium, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid sodium has excellent anticancer and antimicrobial properties. Usnic acid sodium significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK	Cancer
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .

HY-N11775

Eudebeiolide B Plebeiolide D	NF-κB Akt Nuclear Factor of activated T Cells (NFAT) Phosphatase	Metabolic Disease
Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating *RANKL*-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .

HY-N12507

Eupenicisirenin C	STING NF-κB	Others
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .

HY-N2119R

Sciadopitysin (Standard)	TNF Receptor NF-κB	Inflammation/Immunology
Sciadopitysin (Standard) is the analytical standard of Sciadopitysin. This product is intended for research and analytical applications. Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .

HY-158098

FGFR1 inhibitor-11	FGFR	Metabolic Disease
FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .

HY-118482

Sauristolactam Saurolactam	Others	Neurological Disease
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .

HY-125911

Gossypin	NF-κB	Cardiovascular Disease Inflammation/Immunology Cancer
Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .

HY-N0499R

Cyanidin Chloride (Standard)	RANKL/RANK	Cancer
Cyanidin (Chloride) (Standard) is the analytical standard of Cyanidin (Chloride). This product is intended for research and analytical applications. Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .

HY-130237

Cinnamtannin B-1	Reactive Oxygen Species	Metabolic Disease Cancer
Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .

HY-161869

LSD1-IN-32	Histone Methyltransferase	Metabolic Disease
LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC₅₀ value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .

HY-N12604

Penicisteck acid F	NF-κB	Others
Penicisteck acid F (Compound 2) is a Marine derived tanzanic acid derivative that is a NF-κB inhibitor. Penicisteck acid F inhibits osteoclast expression by decreasing RANKL-induced IκBα degradation, NF-κB p65 nuclear translocation, NFATc1 activation and nuclear translocation, and related mRNA expression. Penicisteck acid F can be used in osteoporosis research .

HY-113756A

Latanoprost acid 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor . Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes .

HY-B1246

Thonzonium bromide 5 Publications Verification	Bacterial Proton Pump	Infection
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC₅₀=69 μM) .

HY-N6973R

Boldine (Standard)	RANKL/RANK	Inflammation/Immunology
Boldine (Standard) is the analytical standard of Boldine. This product is intended for research and analytical applications. Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects. Boldine suppresses osteoclastogenesis, improves bone destruction by down-regulating the *OPG/RANKL/RANK* signal pathway and may be a potential therapeutic agent for rheumatoid arthritis .

HY-110318

VUF11207 fumarate 2 Publications Verification	CXCR	Inflammation/Immunology Cancer
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .

HY-125911R

Gossypin (Standard)	NF-κB	Cardiovascular Disease Inflammation/Immunology Cancer
Gossypin (Standard) is the analytical standard of Gossypin. This product is intended for research and analytical applications. Gossypin is a flavone isolated from?Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-N0751

Scutellarin Maximum Cited Publications 9 Publications Verification	STAT Akt HIV	Infection Cancer
Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the STAT3/Girdin/Akt signaling in HCC cells, and inhibits RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts. Scutellarin is active against HIV-1IIIB, HIV-1(74V) and HIV-1KM018 with EC₅₀s of 26 μM, 253 μM and 136 μM, respectively.

HY-B0012

Pamidronic acid 1 Publications Verification	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of *RANKL* and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	RANKL/RANK	Metabolic Disease Inflammation/Immunology Cancer
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .

HY-N6973

Boldine 1 Publications Verification	RANKL/RANK Apoptosis	Inflammation/Immunology
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the *OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research .

HY-130237R

Cinnamtannin B-1 (Standard)	Reactive Oxygen Species	Metabolic Disease Cancer
Cinnamtannin B-1 (Standard) is the analytical standard of Cinnamtannin B-1. This product is intended for research and analytical applications. Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .

HY-B0012B

Pamidronic acid sodium	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of *RANKL* and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-113756AR

Latanoprost acid (Standard)	Prostaglandin Receptor	Inflammation/Immunology
Latanoprost acid (Standard) is the analytical standard of Latanoprost acid. This product is intended for research and analytical applications. Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor . Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes .

HY-168090

Anti-osteoporosis agent-11	p38 MAPK NF-κB RANKL/RANK	Endocrinology
Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC₅₀ value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking *rankl*-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .

Cat. No.	Product Name	Target	Research Area

HY-P990165

*Anti-Mouse RANKL/CD254 Antibody (IK22/5)*	Inhibitory Antibodies	Others
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse RANKL/CD254.

HY-P9958

Denosumab 1 Publications Verification Immunoglobulin G2; Ranmark	NF-κB	Cancer
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of *RANKL* (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK	Cancer
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .

HY-P99966

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Species:	Human (5) Mouse (5) Cynomolgus (1)
Tag:	His (4) Tag Free (3) Fc (4) Flag (2)
Source:	HEK293 (8) CHO (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73386

	RANKL/TNFSF11 Protein, Human (HEK293) 2 Publications Verification Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293) is a recombinant human RANKL (G64-D245) without any tag, which is produced in HEK293 cell.

HY-P73388

	RANKL/TNFSF11 Protein, Mouse (HEK293, Fc) 1 Publications Verification Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Mouse	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Mouse (HEK293, Fc) is a recombinant mouse RANKL (R72-D316) with N-terminal hFc tag, which is produced in HEK293.

HY-P75999

	RANKL/TNFSF11 Protein, Cynomolgus (HEK293, Fc) Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Cynomolgus	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G63-D244) with N-terminal hFc tag, which is produced in HEK293.

HY-P7424

	RANKL/TNFSF11 Protein, Human Maximum Cited Publications 7 Publications Verification rHuRANK L/TNFSF11; TRANCE; CD254	Human	E. coli
	RANKL (TNFSF11), a type II transmembrane protein, is receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human is a recombinant human RANKL (I140-D317) without any tag, which is produced in E.coli.

HY-P7425

	RANKL/TNFSF11 Protein, Mouse 5 Publications Verification rMuRANK L/TNFSF11; TRANCE; CD254	Mouse	E. coli
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Mouse is a recombinant mouse RANKL (Q137-D316) without tag, which is produced in E.coli.

HY-P73682

	RANK L/TNFSF11 Protein, Human (HEK293, mFc) Tumor necrosis factor ligand superfamily member 11; ODF; RANKL; CD254; TNFSF11	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, Fc) is a recombinant human RANKL (G63-D244) with N-terminal mFc tag, which is produced in HEK293 cell.

HY-P78376

	RANKL/TNFSF11 Protein, Human (HEK293, His-Flag) ODF; OPGL; RANKL; TRANCE; CD254; sOdf; TNFSF11; OPTB2	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G63-D244) with N-terminal his and flag tag, which is produced in HEK293.

HY-P700259

	RANKL/TNFSF11 Protein, Mouse (CHO, His) rMuRANKL/TNFSF11, His; TRANCE; CD254	Mouse	CHO
	RANKL/TNFSF11 Protein, Mouse (CHO) is a TNF-related activation-induced cytokine produced in CHO. Mouse and human RANK Ligand share 85% amino acid identity. RANK L/TNFSF11 Protein, Mouse (CHO, His) induces the activation of the c-jun N terminal kinase, enhances T cell growth and dendritic cell function, induces osteoclastogenesis, and lymph node organogenesis.

HY-P73387

	RANKL/TNFSF11 Protein, Human (HEK293, hFc) Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G64-D245) with N-terminal hFc tag, which is produced in HEK293.

HY-P703819

	RANKL/TNFSF11/CD254 Protein, Mouse (HEK293, His)	Mouse	HEK293

HY-P7425C

	RANKL/TNFSF11 Protein, Mouse (HEK293, His, Flag) soluble Receptor Activator of NF-kB Ligand; TNFSF11; TRANCE (TNF-Related Activation-induced Cytokine); OPGL; ODF (Osteoclast Differentiation Factor); CD254; sRNAK Ligand	Mouse	HEK293
	RANKL/TNFSF11 Protein, Mouse (HEK293, His, Flag) is the recombinant mouse-derived RANKL/TNFSF11, expressed by HEK293 , with C-Flag, C-6*His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81124

	RANKL/CD254 Antibody OPGL; CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN.	WB, IHC-P, ELISA	Human, Mouse, Rat
	RANKL/CD254 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL/CD254 Antibody can be used for: WB, IHC-P, ELISA expriments in human, mouse, rat background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks